Lazard Q3 Earnings Beat Estimates, Advisory Revenues & AUM Rise Y/Y — Positive

LAZ   Zacks Investment Research — October 24, 2025

LAZ's Q3 earnings top estimates as advisory and asset management revenues rose y/y, supported by higher AUM and solid liquidity.

image for news Lazard Q3 Earnings Beat Estimates, Advisory Revenues & AUM Rise Y/Y

Top Stock Movers Now: Ford Motor, AMD, Deckers Outdoor, Newmont, and More — Positive

AMD  DECK  F  NEM   Investopedia — October 24, 2025

The Dow, S&P 500, and Nasdaq climbed to record highs in intraday trading Friday after a flurry of strong corporate earnings and the release of a cooler-than-expected inflation report.

image for news Top Stock Movers Now: Ford Motor, AMD, Deckers Outdoor, Newmont, and More

Wall Street Roundup: Are We In A Bubble? — Neutral

AAPL  BYND  DIA  DNUT  GM  GOOG  GOOGL  GPRO  INTC  IRBT  MEME  META  MSFT  NDAQ  NFLX  NVDA  QQQ  SPY  TSLA  WMT   Seeking Alpha — October 24, 2025

Tesla (TSLA) earnings were mixed, with margin pressure and near-term uncertainty, but revenue beat expectations and investors remain in wait-and-see mode. GM surged 15% after beating earnings and raising guidance, as tariff impacts were less severe and market share reached a multi-year high.

image for news Wall Street Roundup: Are We In A Bubble?

Alphabet has been the best-performing Magnificent 7 stock this year, supported by robust Google Cloud and AI advancements. Momentum was recently reinforced by Anthropic's endorsement of additional compute capacity on Google's in-house TPUs, validating diversification of growth opportunities for its cloud unit. This is expected to reinforce Google Cloud's market share gains, and narrow the lead currently commanded by rivals Microsoft Azure and Amazon Web Services.

image for news Alphabet Q3 2025 Earnings Preview: Anthropic Deal Signals Next Phase Of Cloud Acceleration

Relay Therapeutics Is A Buy For Its Superb Safety Data — Positive

RLAY   Seeking Alpha — October 24, 2025

Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI3Kα inhibitors, positioning RLAY as undervalued and ahead in clinical development.

image for news Relay Therapeutics Is A Buy For Its Superb Safety Data

MONCKS CORNER, S.C.--(BUSINESS WIRE)--After a thorough, expert-driven review of proposals from global leaders in the nuclear power industry, the Santee Cooper Board of Directors approved today a letter of intent with Brookfield Asset Management (“Brookfield”) to guide final, exclusive negotiations with Brookfield concerning the two partially built AP1000 nuclear units in Fairfield County, SC. The letter of intent establishes a six-week initial project feasibility period. In that period, the par.

image for news Santee Cooper Selects Brookfield Asset Management to Proceed with Nuclear Project

Proposed Offer Represents 51% Premium to Unaffected Stock Price LOS ANGELES , Oct. 24, 2025 /PRNewswire/ -- George Raymond Zage III and James Fu Bin Lu (together, the "Proposing Shareholders"), who along with affiliated entities beneficially own in aggregate more than 60% of the outstanding shares of common stock of Grindr Inc. (the "Company" or "Grindr") (NYSE: GRND), today submitted a non-binding proposal (the "Proposal") to acquire all outstanding shares of the Company's common stock not already owned by the Proposing Shareholders and their affiliates (the "Minority Shares") in a going-private transaction (the "Acquisition"). The Proposal contemplates consideration of $18.00 …

image for news Majority Grindr Shareholders George Raymond Zage III and James Fu Bin Lu Submit Non-Binding Offer to Acquire All Outstanding Shares of Grindr Inc. for $18.00 per Share

Hilltop Holdings Q3 Earnings Beat on Y/Y Increase in Revenues — Positive

HTH   Zacks Investment Research — October 24, 2025

HTH posts a strong Q3 beat as higher interest income, better credit quality and loan growth boost results despite rising expenses.

image for news Hilltop Holdings Q3 Earnings Beat on Y/Y Increase in Revenues

Why Amphenol (APH) Might be Well Poised for a Surge — Positive

APH   Zacks Investment Research — October 24, 2025

Amphenol (APH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

image for news Why Amphenol (APH) Might be Well Poised for a Surge

Pagaya: The Foundation Is Set For A Long-Term Rerating — Positive

PGY   Seeking Alpha — October 24, 2025

Pagaya leverages AI to serve high-risk borrowers rejected by traditional banks, tapping into a vast underserved market. PGY has achieved GAAP profitability in the last two quarters, with operational leverage. PGY's strong partnerships, robust credit quality, and scalable business model support a positive long-term outlook and continued network volume growth.

image for news Pagaya: The Foundation Is Set For A Long-Term Rerating

Orion Integrity spacecraft connected with the SLS rocket, readying for historic crewed journey to the Moon KENNEDY SPACE CENTER, Fla. , Oct. 24, 2025 /PRNewswire/ -- In a move signifying mission readiness, NASA's Exploration Ground Systems (EGS) team recently joined and connected the Lockheed Martin (NYSE: LMT)-developed Orion spacecraft with the Space Launch System (SLS) rocket for the upcoming Artemis II mission.

image for news Orion Spacecraft Completes Major Stacking Milestone Ahead of Artemis II Mission

Is the oil rally just getting started or running out of steam? Should you buy gold and silver now?

image for news Is the oil rally just getting started or running out of steam? Should you buy gold and silver now?

Baker Hughes Company (BKR) Q3 2025 Earnings Call Transcript — Neutral

BKR   Seeking Alpha — October 24, 2025

Baker Hughes Company (NASDAQ:BKR ) Q3 2025 Earnings Call October 24, 2025 9:30 AM EDT Company Participants Chase Mulvehill - Vice President of Investor Relations Lorenzo Simonelli - Chairman, President & CEO Ahmed Moghal - Executive VP & CFO Conference Call Participants John Anderson - Barclays Bank PLC, Research Division Arun Jayaram - JPMorgan Chase & Co, Research Division Stephen Gengaro - Stifel, Nicolaus & Company, Incorporated, Research Division Scott Gruber - Citigroup Inc., Research Division James West - Melius Research LLC Marc Bianchi - TD Cowen, Research Division Presentation Operator Good day, ladies and gentlemen, and welcome to the …

image for news Baker Hughes Company (BKR) Q3 2025 Earnings Call Transcript

Deckers Brands fiscal Q2 earnings of $1.82 per share beat estimates, but full-year revenue guidance missed Wall Street's forecast. Sales of HOKA running shoes softened, while UGG boots outperformed expectations.

image for news Deckers Brands stock sinks more than 12% after soft outlook raises concerns about Hoka, Ugg growth

PGY vs. OMF: Which Consumer Credit Stock Is Better Placed for Growth? — Positive

OMF  PGY   Zacks Investment Research — October 24, 2025

Pagaya leans on AI and asset-light growth, while OneMain bets on brick-and-mortar lending and shareholder returns.

image for news PGY vs. OMF: Which Consumer Credit Stock Is Better Placed for Growth?

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and exceeded desired pharmacokinetic targets New preclinical data show that NBD1 stabilizers restored the half-life of F508del-CFTR up to wild-type levels WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced data presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in …

image for news Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference

Will Global Payments (GPN) Beat Estimates Again in Its Next Earnings Report? — Positive

GPN   Zacks Investment Research — October 24, 2025

Global Payments (GPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

image for news Will Global Payments (GPN) Beat Estimates Again in Its Next Earnings Report?

Will Dutch Bros (BROS) Beat Estimates Again in Its Next Earnings Report? — Positive

BROS   Zacks Investment Research — October 24, 2025

Dutch Bros (BROS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

image for news Will Dutch Bros (BROS) Beat Estimates Again in Its Next Earnings Report?

Will Axos Financial (AX) Beat Estimates Again in Its Next Earnings Report? — Positive

AX   Zacks Investment Research — October 24, 2025

Axos Financial (AX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

image for news Will Axos Financial (AX) Beat Estimates Again in Its Next Earnings Report?

Will Cushman & Wakefield (CWK) Beat Estimates Again in Its Next Earnings Report? — Positive

CWK   Zacks Investment Research — October 24, 2025

Cushman & Wakefield (CWK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

image for news Will Cushman & Wakefield (CWK) Beat Estimates Again in Its Next Earnings Report?